Anti-Factor V monoclonal antibody, clone BCW-5106

OBJECTIVE This study aimed to establish the equivalence, reliability, and validity of the Multiple Sclerosis Self-Management Scale Turkish Version (MSSM-T). METHODS This methodological study consisted of 240 multiple sclerosis (MS) patients who were followed in an outpatient clinic of a university hospital between October 2016 and April 2017. Data were collected using the demographic characteristics form and the 24-item MSSM-T. Language equivalence, content validity, and construct validity methods were used for the validity of the scale; internal consistency, item analysis, and test-retest methods were used for the reliability. Explanatory factor analysis was used for construct validity, and principal component analysis and varimax rotation were used in the analysis of factor structure. RESULTS The item-total correlations for the Turkish version were found to be sufficient (between 0.238 and 0.674). The Cronbach alpha reliability coefficient was 0.85, indicating high reliability. The test-retest reliability coefficient was 0.84, indicating high consistency. The Turkish version was found to have 5 factors for the 24 items (F1, healthcare provider relationship/communication; F2, knowledge and information about MS; F3, treatment adherence/barriers; F4, maintaining health behavior; and F5, social/family support), which accounted for the 62.584% of the characteristics in question. CONCLUSION The MSSM-T is valid and reliable in determining the self-management behaviors of patients with MS for Turkish patients.

The reason for this exploration was to develop gastro-retentive drug delivery systems (GRDDS) of loratadine (LTD) to lengthen the gastric residence time (GRT) by using different polymers like hydroxypropyl methyl celluloses (i.e., HPMC K4 M, HPMC K15 M, HPMCK 100 M), xanthan gum and other excipients such as microcrystalline cellulose (MCC), sodium bicarbonate (NaHCO3), magnesium stearate. All LTD floating formulations (F1-F18) prepared by the direct compression technique and evaluated. Fourier Transformed Infrared Spectroscopy (FTIR) studies showed that there are no drug excipient interactions. All LTD effervescent floating matrix tablets (F1-F18) were assessed for various pre-and post-compression parameters like weight variation (mg), hardness (kg/cm(2)), thickness (mm), friability (%), drug content (%), in-vitro buoyancy (h), in-vivo buoyancy (h) and in-vitro dissolution (%) and resulted found within pharmacopoeial limits. The drug release and floating property depended upon the polymer type as well as polymer proportions. The floating lag time (FLT) and total floating time (TFT) of all prepared formulations (F1-F18) showed less than 90 sec and >= 12 hours, respectively. The cumulative percentage (%) of drug release ranged from 56.87 +/- 0.13% (F12) to 99.87 +/- 1.05% (F15) and optimized formulation (F5) was showed 99.82 +/- 1.63% of drug release in 12 h. The in-vitro drug release of LTD effervescent floating tablets followed the non-fickian diffusion-controlled release and is best explained by the Korsmeyer-Peppas equation. All the formulations were subjected to various kinetic models, and F5 formulation was optimized as it followed the zero-order kinetics. The optimized formulation (F5) subjected to an in-vivo study, and the results of radiographic images shown gastric resident time (GRT) of 6 +/- 0.5 hours (n=3). From the in-vivo studies it was evident that the GRT increased by floating mechanism.